Should clotting factors be screened in women planning to initiate systemic hormone therapy, and if so, which specific thrombophilia assays are recommended?

Routine Thrombophilia Screening Is NOT Recommended for Women Starting Hormone Therapy

Routine screening for clotting factors should NOT be performed in women planning to initiate systemic hormone therapy. The consensus across multiple guidelines is clear: routine thrombophilia screening is not appropriate due to the rarity of these conditions, high cost, and limited impact on clinical decision-making 1, 2.

When to Consider Selective Testing

Testing should be limited to specific high-risk scenarios where results will actually change management:

Test Only If:

1. First-degree family history of VTE before age 60 2

   • This is the primary indication for pre-hormone therapy screening
   • Family history must be in a parent or sibling, not distant relatives

2. Known family member with high-risk thrombophilia 3

   • Specifically: homozygous Factor V Leiden or Factor II G20210A
   • Or known antithrombin, protein C, or protein S deficiency in first-degree relatives

3. Personal history of VTE (absolute contraindication to combined estrogen-progestin therapy regardless of testing) 2

Which Tests to Order (When Indicated)

If testing is warranted based on the above criteria, order this specific panel 2:

• Prothrombin time (PT)
• Activated partial thromboplastin time (aPTT)
• Antithrombin level
• Protein C level
• Protein S level
• Factor V Leiden mutation
• Prothrombin (Factor II) G20210A mutation

Do NOT test for MTHFR variants - these have no proven association with VTE risk and should not be part of thrombophilia evaluation 3.

Clinical Decision Algorithm

For Women WITHOUT Risk Factors:

• No testing required
• Proceed with hormone therapy based on standard contraindications
• Counsel on VTE warning signs

For Women WITH First-Degree Family History of VTE <60 years:

• Perform thrombophilia panel (listed above)
• If positive for high-risk thrombophilia (homozygous Factor V Leiden, Factor II G20210A, or deficiencies):
  • Avoid combined estrogen-progestin therapy 2
  • Consider progestin-only options or non-hormonal alternatives
• If negative or low-risk thrombophilia:
  • May proceed with hormone therapy
  • Consider transdermal estrogen (lower VTE risk than oral) 4
  • Enhanced counseling on VTE symptoms

For Women WITH Personal History of VTE:

• No testing needed - combined estrogen-progestin therapy is absolutely contraindicated regardless of thrombophilia status 2
• Offer progestin-only methods or non-hormonal alternatives
• If thrombophilia testing desired for family planning purposes, perform after acute event and off anticoagulation for appropriate timing

Important Caveats

Timing matters: If testing is performed, do NOT test during acute thrombosis or within 3 months of anticoagulation initiation, as results will be unreliable 5, 6.

Transdermal vs oral estrogen: The most recent evidence shows transdermal estrogen formulations have substantially lower VTE risk than oral preparations 4. In women with borderline risk factors, transdermal routes may be preferred even without formal thrombophilia testing.

Progestin-only options: These do not increase VTE risk and remain safe alternatives when combined estrogen-progestin therapy is contraindicated 2.

The key principle is that testing should only be performed when results will change management decisions. For the vast majority of women initiating hormone therapy, clinical history alone is sufficient to guide safe prescribing without laboratory screening 1, 2, 6.